94 211

Cited 0 times in

Effectiveness of Convalescent Plasma Therapy in Severe or Critically Ill COVID-19 Patients: A Retrospective Cohort Study

DC Field Value Language
dc.contributor.author구남수-
dc.contributor.author김무현-
dc.contributor.author김신영-
dc.contributor.author김정호-
dc.contributor.author백예지-
dc.contributor.author손유진-
dc.contributor.author송영구-
dc.contributor.author안진영-
dc.contributor.author염준섭-
dc.contributor.author이경화-
dc.contributor.author정수진-
dc.contributor.author조윤숙-
dc.contributor.author최준용-
dc.contributor.author현종훈-
dc.contributor.author안미영-
dc.date.accessioned2021-12-28T16:49:41Z-
dc.date.available2021-12-28T16:49:41Z-
dc.date.issued2021-09-
dc.identifier.issn0513-5796-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/186815-
dc.description.abstractPurpose: Coronavirus disease-2019 (COVID-19) is a novel respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); there are few specific treatments. Convalescent plasma (CP), donated by people who have recovered from COVID-19, is an investigational therapy for severe or critically ill patients with COVID-19. Materials and methods: This retrospective cohort study evaluated the effectiveness of CP therapy in patients with severe or life-threatening cases of COVID-19 at two hospitals in Seoul, Korea, between May and September 2020. Clinical outcomes were evaluated in 20 patients with CP therapy in a descriptive manner. Additionally, the changes in cycle threshold (Ct) values of 10 patients with CP therapy were compared to those of 10 controls who had the same (±0.8) initial Ct values but did not receive CP. Results: Of the 20 patients (mean age 66.6 years), 18 received high-dose oxygen therapy using mechanical ventilators or high-flow nasal cannulas. Systemic steroids were administered to 19 patients who received CP. The neutralizing antibody titers of the administered CP were between 1:80 and 1:10240. There were two ABO-mismatched transfusions. The World Health Organization ordinal scale score and National Institutes of Health severity score improved in half of the patients within 14 days. Those who received CP showed a higher increase in Ct values at 24 h and 72 h after CP therapy compared to controls with similar initial Ct values (p=0.002). No transfusion-related side effects were observed. Conclusion: CP therapy may be a potential therapeutic option in severe or critically ill patients with COVID-19.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherYonsei University-
dc.relation.isPartOfYONSEI MEDICAL JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAged-
dc.subject.MESHCOVID-19* / therapy-
dc.subject.MESHCritical Illness-
dc.subject.MESHHumans-
dc.subject.MESHImmunization, Passive*-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHUnited States-
dc.titleEffectiveness of Convalescent Plasma Therapy in Severe or Critically Ill COVID-19 Patients: A Retrospective Cohort Study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorYunSuk Cho-
dc.contributor.googleauthorYuJin Sohn-
dc.contributor.googleauthorJongHoon Hyun-
dc.contributor.googleauthorYaeJee Baek-
dc.contributor.googleauthorMooHyun Kim-
dc.contributor.googleauthorJungHo Kim-
dc.contributor.googleauthorJinYoung Ahn-
dc.contributor.googleauthorSuJin Jeong-
dc.contributor.googleauthorNamSu Ku-
dc.contributor.googleauthorJoon Sup Yeom-
dc.contributor.googleauthorMiYoung Ahn-
dc.contributor.googleauthorDongHyun Oh-
dc.contributor.googleauthorJaePhil Choi-
dc.contributor.googleauthorSinYoung Kim-
dc.contributor.googleauthorKyoungHwa Lee-
dc.contributor.googleauthorYoungGoo Song-
dc.contributor.googleauthorJunYong Choi-
dc.identifier.doi10.3349/ymj.2021.62.9.799-
dc.contributor.localIdA00189-
dc.contributor.localIdA04521-
dc.contributor.localIdA00675-
dc.contributor.localIdA00902-
dc.contributor.localIdA05921-
dc.contributor.localIdA05924-
dc.contributor.localIdA02037-
dc.contributor.localIdA02267-
dc.contributor.localIdA02353-
dc.contributor.localIdA04620-
dc.contributor.localIdA03638-
dc.contributor.localIdA05940-
dc.contributor.localIdA04191-
dc.contributor.localIdA05944-
dc.relation.journalcodeJ02813-
dc.identifier.eissn1976-2437-
dc.identifier.pmid34427065-
dc.subject.keywordCOVID-19-
dc.subject.keywordConvalescent plasma treatment-
dc.subject.keywordcycle threshold (Ct) value-
dc.subject.keywordneutralizing antibody-
dc.contributor.alternativeNameKu, Nam Su-
dc.contributor.affiliatedAuthor구남수-
dc.contributor.affiliatedAuthor김무현-
dc.contributor.affiliatedAuthor김신영-
dc.contributor.affiliatedAuthor김정호-
dc.contributor.affiliatedAuthor백예지-
dc.contributor.affiliatedAuthor손유진-
dc.contributor.affiliatedAuthor송영구-
dc.contributor.affiliatedAuthor안진영-
dc.contributor.affiliatedAuthor염준섭-
dc.contributor.affiliatedAuthor이경화-
dc.contributor.affiliatedAuthor정수진-
dc.contributor.affiliatedAuthor조윤숙-
dc.contributor.affiliatedAuthor최준용-
dc.contributor.affiliatedAuthor현종훈-
dc.citation.volume62-
dc.citation.number9-
dc.citation.startPage799-
dc.citation.endPage805-
dc.identifier.bibliographicCitationYONSEI MEDICAL JOURNAL, Vol.62(9) : 799-805, 2021-09-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Laboratory Medicine (진단검사의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.